Stockreport

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Molecular Partners AG - American Depositary Shares  (MOLN) 
PDF Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/ref [Read more]